Indivina

Medroxyprogesterone acetate and estradiol valerate, the active ingredients in Indivina, are a combined estrogen and progestogen presented as an oral tablet for systemic use. They replace deficient endogenous hormones, alleviate menopausal vasomotor symptoms, prevent osteoporosis, and manage estrogen deficiency in post‑menopausal women.

GNH USA supplies Indivina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including Europe, Asia and the Americas, with established quality‑assured distribution networks and adhering to stringent regulatory standards, ensuring product integrity from manufacturing to delivery.

Indivina, a combined estrogen‑progestogen therapy, is indicated for conditions related to estrogen deficiency and hormonal regulation.

Menopausal hormone therapy: alleviates vasomotor symptoms, prevents bone loss, and improves urogenital health in post‑menopausal women. Estrogen deficiency symptoms: restores hormonal balance, reducing hot flashes, night sweats, and mood disturbances. Premenstrual syndrome: stabilizes hormonal fluctuations, reducing menstrual‑related discomfort and mood changes.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight gain - Bloating - Mood changes Serious or Rare Side Effects: - Venous thromboembolism - Stroke or transient ischemic attack - Myocardial infarction - Liver function abnormalities - Gallbladder disease - Increased risk of breast cancer

Precautions: - Cardiovascular assessment: evaluate history of thromboembolic or heart disease before initiating therapy. - Liver function monitoring: check hepatic enzymes periodically during treatment. - Breast health surveillance: perform regular clinical examinations and imaging as indicated. - Diabetes management: monitor blood glucose as hormonal changes may affect glycemic control. - Smoking cessation: advise patients to stop smoking to reduce vascular risk. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Interactions: Major Interactions (Avoid): - Concomitant estrogen‑containing products: additive risk of thromboembolic events. - Anticoagulants (e.g., warfarin): may diminish anticoagulant effectiveness. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations of medroxyprogesterone. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce hormone levels, decreasing efficacy. - Selective serotonin reuptake inhibitors (e.g., paroxetine): can affect metabolism of estradiol. - Antihypertensive agents: hormonal therapy may alter blood pressure control.